Ingersoll Rand Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong revenue and EPS growth, robust M&A activity, and positive momentum in short-cycle businesses, with guidance reaffirmed for the year. Tariff and Middle East risks are being managed, and life sciences and innovation continue to drive segment outperformance.
-
The business continues to expand through disciplined M&A, robust recurring revenue growth, and targeted investments in innovation and under-penetrated regions. Margin profiles remain strong, with further expansion expected as productivity and restructuring actions take hold.
-
Momentum in orders and organic growth is evident across regions, with recurring revenue more than doubling in two years. Margin expansion continues through pricing and productivity, while capital allocation remains focused on bolt-on M&A, especially in core and life sciences segments.
-
Strong revenue growth, margin expansion, and disciplined M&A have driven significant value creation and market outperformance. The life science platform is a key growth area, leveraging recurring consumables, global reach, and cross-portfolio synergies. Margin outlook remains robust, with continued focus on strategic acquisitions and operational excellence.
Fiscal Year 2025
-
Q4 and full-year 2025 saw strong order and revenue growth, robust recurring revenue, and disciplined M&A. 2026 guidance projects modest revenue and EPS growth, with margin pressures from tariffs and investments, but continued strength in life sciences and recurring revenue.
-
Q3 delivered strong adjusted EBITDA and EPS growth, with robust order momentum and disciplined capital deployment. Tariff headwinds and delayed price realization impacted guidance, but proactive pricing and cost actions position the company for margin recovery in 2026.
-
M&A remains a core growth driver, with a focus on high-margin, technology-rich bolt-ons and rapid integration. Recurring revenue from service contracts is expanding, targeting $1 billion by 2027. Regional growth is strongest in Europe, India, and underpenetrated markets, while U.S. demand is stable but delayed by tariff uncertainty. Margins are set to improve in the year's second half.
-
Raised full-year guidance on revenue, adjusted EBITDA, and EPS after strong Q2 results, robust backlog, and continued M&A activity. Segment performance was solid, with notable growth in orders and revenue, despite margin pressures from volume and tariffs. Liquidity and balance sheet remain strong.
-
Organic orders grew 3-3.5% in Q1, with stable demand and positive lead indicators despite tariff uncertainty. Recurring revenue surpassed $300 million, driven by expansion beyond compressors and IIoT adoption. M&A activity remains focused on bolt-ons, supporting growth and margin expansion, especially in life sciences.
-
Over five years, the business has transformed through major divestitures and 65+ acquisitions, showing resilience and steady growth. Q1 saw 3% organic order growth, with strong recurring revenue momentum and ongoing margin expansion. M&A remains active, with a focus on bolt-on deals and operational improvements at ILC Dover.
-
Q1 2025 saw strong order growth, record free cash flow, and robust M&A activity, with prudent guidance maintained amid tariff headwinds and macro uncertainty. Segment performance was mixed, but recurring and aftermarket revenues grew, and capital allocation remains focused on bolt-on acquisitions and share repurchases.
-
Q4 results showed slight organic order declines, but excluding China, growth was positive. 2025 guidance targets 1%-3% organic growth, with Americas leading and China stable. M&A remains active, recurring revenue is expanding, and margin improvement is expected as integrations progress.
-
Over five years, the company transformed through divestitures, 60+ acquisitions, and a focus on core technologies, driving margin expansion and global growth. Organic growth is guided at 1%-3%, with strong recurring revenue and a robust M&A pipeline supporting future performance.
Fiscal Year 2024
-
Double-digit adjusted EPS growth and record margins were achieved in 2024, with strong free cash flow and disciplined M&A driving expansion. 2025 guidance calls for 3%-5% revenue growth, stable end markets, and continued margin strength, supported by robust pipelines and ongoing operational execution.
-
Recognized for ESG leadership, 66% of the portfolio now features sustainable attributes, with validated SBTi targets and ambitious new water and decarbonization goals. Strategic acquisitions and innovation drive expansion into high-growth sustainable markets, while recurring revenue and operational excellence reinforce long-term value.
-
M&A remains central, with ILC Dover expanding the life sciences platform and opening new M&A opportunities. Recurring revenue is on track to reach $1 billion by 2027, with global CARE contract adoption. Margins are strong, with further gains expected from bolt-on M&A and recurring revenue.
-
Q3 2024 saw record orders, revenue, and margin expansion, with strong free cash flow and double-digit EPS growth. Guidance for 2024 was slightly reduced due to shipment timing, but order momentum, M&A activity, and backlog remain robust, supporting a positive outlook for 2025.
-
A disciplined M&A strategy, strong ownership culture, and focus on sustainability and digitalization drive robust growth and margin expansion. Life sciences and recurring revenue are key growth areas, with global mega projects and a strong demand engine supporting future performance.
-
Stable market conditions persist with steady order trends and strong demand generation, supported by digital tools and AI. Recent acquisitions and a robust M&A pipeline drive growth, while margin expansion continues across segments. Recurring revenue and service innovations are set to boost profitability.
-
Q2 2024 saw record results with 16% Adjusted EBITDA growth and 22% higher EPS year-over-year, prompting a raised full-year outlook. Recent acquisitions, especially ILC Dover, are driving inorganic growth, while China remains a headwind for organic revenue.
-
Americas lead regional performance, while China remains a headwind. Demand generation and digitalization drive growth, with a robust M&A pipeline and a focus on recurring revenue. Legacy asbestos liabilities were divested, reducing risk and strengthening the balance sheet.